GSK spun off Haleon to form a new consumer healthcare entity ... In 2023, the company reported full-year revenues of $14.7bn, up 4% year-on-year, operating profit of $2.6bn, up 9.4% and ...

Analysis of the full trial data, including the key secondary endpoint of overall survival (OS), is ongoing, but at the moment that data is “immature”, said GSK. In October, GSK reported new ...

Coolers full of vaccine strapped to their motorbikes ... mostly, as she is unable to form words. Her mother, Nazma, had been outside with the baby when we arrived; in these rooms nine families ...

GSK was able to avert industrial action at some of its UK facilities last year after agreeing a pay deal – but with the cost-of-living crisis still in full swing ... and other form of borrowing.

Please see full Prescribing Information for AREXVY ... those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024.

Though prescribing climate-friendly inhalers is environmentally sound, some experts warn certain patients may be overlooked.

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

In a dramatic turn of events that makes for some great storytelling, Cidara's novel drug-Fc conjugate, once locked up in a ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Please consult the full Summary of Product Characteristics ... those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024.

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...